Insmed Inc (INSM)vsPTC Therapeutics Inc (PTCT)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
PTCT
PTC Therapeutics Inc
$66.75
+3.42%
HEALTHCARE · Cap: $5.34B
Smart Verdict
WallStSmart Research — data-driven comparison
PTC Therapeutics Inc generates 185% more annual revenue ($1.73B vs $606.42M). PTCT leads profitability with a 39.4% profit margin vs -2.1%. PTCT appears more attractively valued with a PEG of 0.81. PTCT earns a higher WallStSmart Score of 45/100 (D).
INSM
Hold39
out of 100
Grade: F
PTCT
Hold45
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for INSM.
Margin of Safety
-21.6%
Fair Value
$58.34
Current Price
$66.75
$8.41 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Attractively priced relative to earnings
Keeps 39 of every $100 in revenue as profit
Growing faster than its price suggests
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% earnings growth
ROE of -77.4% — below average capital efficiency
Revenue declined 22.7%
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : PTCT
The strongest argument for PTCT centers on P/E Ratio, Profit Margin, PEG Ratio. Profitability is solid with margins at 39.4% and operating margin at -49.6%. PEG of 0.81 suggests the stock is reasonably priced for its growth.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : PTCT
The primary concerns for PTCT are EPS Growth, Return on Equity, Revenue Growth.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while PTCT is a declining play — different risk/reward profiles.
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
PTCT generates stronger free cash flow (-37M), providing more financial flexibility.
Bottom Line
PTCT scores higher overall (45/100 vs 39/100), backed by strong 39.4% margins. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
PTC Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for patients with rare disorders. The company is headquartered in South Plainfield, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?